Coherus Oncology, Inc. (CHRS) vs Journey Medical Corporation (DERM)
A side-by-side comparison of Coherus Oncology, Inc. and Journey Medical Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CHRS
Coherus Oncology, Inc.
$1.05HealthcareDelayed quote: Oct 6, 2026, 12:45 PM EDT
DERM
Journey Medical Corporation
$6.45HealthcareDelayed quote: Oct 6, 2026, 12:44 PM EDT
Total return — CHRS vs DERM
growth of $100 · dividends reinvested · last 5yCHRS -94.0% (-43.0%/yr)DERM -29.6% (-6.8%/yr)DERM compounded faster over this window
Log scale — wide-divergence pair
CHRS DERM
CHRS vs DERM: by the numbers
- •DERM is the larger company ($178M vs $161M market cap).
- •Both run net losses; DERM's is the smaller (-8.95% vs -257.10% net margin).
- •DERM grew revenue faster over the past five years (6.75% vs -33.60% CAGR).
Metrics side by side
Valuation
| Metric | CHRS | DERM |
|---|---|---|
| P/S ratio | 3.17 | 2.60 |
| P/B ratio | 2.65 | 5.53 |
| EV / EBITDA | N/A | 140.62 |
Profitability
| Metric | CHRS | DERM |
|---|---|---|
| Gross margin | 63.55% | 62.24% |
| Operating margin | -425.72% | -13.21% |
| Net margin | -257.10% | -8.95% |
| ROE | -215.26% | -19.01% |
| ROIC | -135.38% | -5.22% |
Growth (annualized)
| Metric | CHRS | DERM |
|---|---|---|
| Revenue CAGR (5Y) | -33.60% | 6.75% |
| Total return CAGR (5Y) | -41.38% | N/A |
Frequently asked
- Which has grown faster, CHRS or DERM?
- Over the past five years, DERM grew revenue faster — CHRS at a -33.60% CAGR versus DERM at 6.75%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.